Biomarin

With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
cell therapy
gene therapy
Novartis
Kite Pharma
Biomarin
Astellas
Flag link:
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
Flag link:
BioMarin gene therapy shows sustained benefit in hemophilia A study
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
Flag link:
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
Yahoo/PR Newswire
Biomarin
DiNAQOR
gene therapy
cardiomyopathy
Flag link:
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
Motley Fool
Biomarin
earnings
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:
BioMarin's Novel Treatment Promises to Disrupt Competitors
BioMarin's Novel Treatment Promises to Disrupt Competitors
Motley Fool
Biomarin
gene therapy
valrox
hemophilia A
Flag link:
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Forbes
Biomarin
valrox
gene therapy
hemophilia A
Flag link:
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
Flag link:
BioMarin sets gene therapy sights beyond hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Biomarin
hemophilia
gene therapy
Flag link:
These 3 Biotech Stocks Could Be Top Stocks in 2020
These 3 Biotech Stocks Could Be Top Stocks in 2020
Motley Fool
Biomarin
Iovance
Immunomedics
Flag link:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
Flag link:
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Flag link:
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Flag link:
Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
Motley Fool
Biomarin
R&D
gene therapy
Europe
Flag link:
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Yahoo/Benzinga
earnings
Eli Lilly
Alexion
Gilead Sciences
Biomarin
Edwards Lifesciences
Baxter International
Integra LifeSciences
Phathom Pharmaceuticals
IPOs
Foamix
Eton Pharmaceuticals
Melinta Therapeutics
Ligand Pharmaceuticals
Flag link:
BioMarin talks down worries on gene therapy data differences
BioMarin talks down worries on gene therapy data differences
Biopharma Dive
Biomarin
gene therapy
hemophilia A
valrox
Flag link:
BioMarin's Roller Coaster Continues
BioMarin's Roller Coaster Continues
Yahoo/Motley Fool
Biomarin
earnings
Flag link:

Pages